The company has a strong pipeline of cancer vaccines in development.
In March 2019, the company dosed its first patient with its HER-Vaxx (IMU131) cancer vaccine for the treatment of HER-2 positive gastric cancer patients.
This marked an important milestone for the company in advancing its Phase II trials.
Additionally, Imugene presented the Phase 1b study results of its HER-Vaxx cancer vaccine at the American Association for Cancer Research (AACR) meeting in April 2019.
Furthermore, positive new data findings from the active immunisation studies for KEY-Vaxx earlier this year provided proof of concept and validation for the human PD-1 cancer vaccine.
The FDA meeting in February 2019 was productive and provided Imugene with a clear roadmap for a successful IND submission and subsequent clinical development of KEY-Vaxx.